12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CTL019: Phase I data

Data from 22 pediatric patients with relapsed or refractory ALL in an open-label, U.S. Phase I trial showed that CTL019 led to complete remission in 19 patients (86%). The first pediatric patient treated remains in remission after 20 months, while 5 pediatric patients have relapsed, including 1 patient who developed new tumor cells that do not express CD19. Additionally, all 5 evaluable adult...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >